北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 血液科  > 期刊论文
学科主题: 临床医学
题名:
Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Intermediate-Risk Acute Myeloid Leukemia Adult Patients in First Complete Remission: A Meta-Analysis of Prospective Studies
作者: Li, Dandan1,2; Wang, Li1,2; Zhu, Honghu3; Dou, Liping1; Liu, Daihong1; Fu, Lin4; Ma, Cong5; Ma, Xuebin6; Yao, Yushi1; Zhou, Lei1,7; Wang, Qian1; Wang, Lijun1; Zhao, Yu1; Jing, Yu1; Wang, Lili1; Li, Yonghui1; Yu, Li1
刊名: PLOS ONE
发表日期: 2015-07-21
DOI: 10.1371/journal.pone.0132620
卷: 10, 期:7
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Multidisciplinary Sciences
研究领域[WOS]: Science & Technology - Other Topics
关键词[WOS]: BONE-MARROW-TRANSPLANTATION ; ACUTE MYELOGENOUS LEUKEMIA ; HIGH-DOSE CYTARABINE ; PROSPECTIVE CONTROLLED-TRIAL ; PROSPECTIVE MULTICENTER TRIAL ; VERSUS-HOST-DISEASE ; POSTREMISSION THERAPY ; INTENSIFICATION CHEMOTHERAPY ; CONSOLIDATION CHEMOTHERAPY ; INTENSIVE CHEMOTHERAPY
英文摘要:

Hematopoietic stem cell transplantation (HSCT) and consolidation chemotherapy have been used to treat intermediate-risk acute myeloid leukemia (AML) patients in first complete remission (CR1). However, it is still unclear which treatments are most effective for these patients. The aim of our study was to analyze the relapse-free survival (RFS) and overall survival (OS) benefit of allogeneic HSCT (alloHSCT) for intermediate-risk AML patients in CR1. A meta-analysis of prospective trials comparing alloHSCT to non-alloHSCT (autologous HSCT [autoHSCT] and/or chemotherapy) was undertaken. We systematically searched PubMed, Embase, and the Cochrane Library though October 2014, using keywords and relative MeSH or Emtree terms, ′allogeneic′; ′acut*′ and ′leukem*/aml/leukaem*/ leucem*/leucaem*′; and ′nonlympho*′ or ′myelo*′. A total of 7053 articles were accessed. The primary outcomes were RFS and OS, while the secondary outcomes were treatment-related mortality (TRM) and relapse rate (RR). Hazard ratios (HR) and 95% confidence intervals (CI) were calculated for each outcome. The primary outcomes were RFS and OS, while the secondary outcomes were TRM and RR. We included 9 prospective controlled studies including 1950 adult patients. Patients with intermediate-risk AML in CR1 who received either alloHSCT or non-alloHSCT were considered eligible. AlloHSCT was found to be associated with significantly better RFS, OS, and RR than non-alloHSCT (HR, 0.684 [95% CI: 0.48, 0.95]; HR, 0.76 [95% CI: 0.61, 0.95]; and HR, 0.58 [95% CI: 0.45, 0.75], respectively). TRM was significantly higher following alloHSCT than non-alloHSCT (HR, 3.09 [95% CI: 1.38, 6.92]). However, subgroup analysis showed no OS benefit for alloHSCT over autoHSCT (HR, 0.99 [95% CI: 0.70, 1.39]). In conclusion, alloHSCT is associated with more favorable RFS, OS, and RR benefits (but not TRM outcomes) than non-alloHSCT generally, but does not have an OS advantage over autoHSCT specifically, in patients with intermediate-risk AML in CR1.

语种: 英语
所属项目编号: 81370635 ; 81170518 ; 81270611 ; 81470010 ; SF2001-5001-07 ; 7151009 ; 201202017 ; Z111107067311070
项目资助者: Doctor Scientific research innovation projects ; National Natural Science Foundation of China ; Capital Medical Development Scientific Research Fund ; Beijing Natural Science Foundation ; National Public Health Grant Research Foundation ; capital of the public health project
WOS记录号: WOS:000358547600044
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/57157
Appears in Collections:北京大学第二临床医学院_血液科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Chinese Peoples Liberat Army Gen Hosp, Dept Hematol, Beijing, Peoples R China
2.Med Coll Chinese PLA, Beijing, Peoples R China
3.Peking Univ, Inst Hematol, Peoples Hosp, Dept Hematol, Beijing 100871, Peoples R China
4.Peking Univ, Hosp 3, Dept Hematol, Beijing 100871, Peoples R China
5.PLA Navy Gen Hosp, Dept Clin Lab, Beijing, Peoples R China
6.PLA Navy Gen Hosp, Tumor Diag & Treatment Ctr, Beijing, Peoples R China
7.202 Hosp PLA, Dept Hematol, Shenyang, Peoples R China

Recommended Citation:
Li, Dandan,Wang, Li,Zhu, Honghu,et al. Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Intermediate-Risk Acute Myeloid Leukemia Adult Patients in First Complete Remission: A Meta-Analysis of Prospective Studies[J]. PLOS ONE,2015,10(7).
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Li, Dandan]'s Articles
[Wang, Li]'s Articles
[Zhu, Honghu]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Li, Dandan]‘s Articles
[Wang, Li]‘s Articles
[Zhu, Honghu]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace